|
270 documents found matching dt:email OR dt:e-mail.
|
|
of 27
Prev
Next
|
|
|
|
Showing 1-10 of 270 documents
|
1.
ADVANTAGE CV Events Table Emails
|
Document Date:
|
20010407
|
|
Author:
|
Scolnick, Edward
|
|
Corporate Author:
|
Merck and Co.
|
|
Recipient:
|
Greene, Douglas
|
|
Corporate Recipient:
|
Merck and Co.
|
|
Document Type:
|
(:email)
|
|
Named Person:
|
Gilmartin, Ray|Silverman, Robert|Blois, David W.|Goldmann, Bonnie J|Reicin, Alise S.|Bertz, Barry|Shapiro, Deborah|Oppenheimer, Leonard|Nies, Alan|Geba, Greg
|
|
Named Organization:
|
U.S. Food and Drug Administration|FDA
|
|
Case Number:
|
Frederick Humeston v. Merck & Co|Brian Hermans v. Merck & Co
|
|
Bates Number:
|
MRKACR0009150
|
|
Bookmark:
|
http://dida.library.ucsf.edu/tid/vio22x10
|
|
| |
2.
ADVANTAGE Ideas Email
|
Document Date:
|
19990322
|
|
Author:
|
Higbee, Rebecca
|
|
Corporate Author:
|
Merck and Co.
|
|
Recipient:
|
Lindemann, Kyra
|
|
Corporate Recipient:
|
Merck and Co.
|
|
Document Type:
|
(:email)
|
|
Named Person:
|
Weiner, Jan|Higbee, Rebecca|Dixon, Mary|Mendez, Leonardo|Bell, Greg|Lindemann, Kyra|Fanelle, Christine
|
|
Named Organization:
|
Merck and Co.|Merck Marketing|Ogilvy & Mather
|
|
Case Number:
|
Frederick Humeston v. Merck & Co|Brian Hermans v. Merck & Co
|
|
Bates Number:
|
MRKADI0024344-MRKADI0024346
|
|
Person Copied:
|
Fanelle, Christine|Weiner, Jan D.
|
|
Bookmark:
|
http://dida.library.ucsf.edu/tid/vio26x10
|
|
| |
3.
ADVANTAGE Investigators Email
|
Document Date:
|
19991130
|
|
Author:
|
Poucket, Jeffrey
|
|
Corporate Author:
|
Merck and Co.
|
|
Recipient:
|
Yarbrough, Caroline
|
|
Corporate Recipient:
|
Merck and Co.
|
|
Document Type:
|
(:email)
|
|
Case Number:
|
Frederick Humeston v. Merck & Co|Brian Hermans v. Merck & Co
|
|
Bates Number:
|
MRKACX0002964-MRKACX0002968
|
|
Person Copied:
|
Reiss, Sandra
|
|
Bookmark:
|
http://dida.library.ucsf.edu/tid/vio23x10
|
|
| |
4.
cv study design
|
Document Date:
|
20011128
|
|
Author:
|
Reicin
|
|
Recipient:
|
Tobert
|
|
Document Type:
|
e-mail
|
|
Case Number:
|
Brian Hermans v. Merck & Co,
|
|
Bates Number:
|
MRK-NJ0326037-2638
|
|
Exhibit Number:
|
P39
|
|
Search Terms in Context:
|
To:
Tobert, Jonathan A.
From:
Reicin, Alise S.
Ce
Bec:
Date:
2001-11-28 2220:42
Subject:
FW: Cv study design
Jonahan
I think you know the VIGOR results-in VIGOR there was a significant reduction in CV outcomes in patients on
naproxen versus patients on vioxx. Ed is interested in evaluating whether Naproxen is in fact a cardioprotective
agent and therefore he is suggesting studies which compare VIOXX + antiplatelet agent versus Naproxen
without an antiplatelet agent (you assume Naproxen is the anti-platelet agent) in patients who need treatment
with aspirin. Since aspirin is the standard of care and does not require steady bid dosing to be effective we think
it unlikely that physicians would want to take patiente off aspim to put them on naproxen.
We wanted to get Rory's opinion on feasability of such a study
thanks
Alise
—Original Message—
From: Demopoulos, Laura A.
Sent: Wednesday, November 21, 2001 9:43 AM
To: Reicin, Alise S.
Subject: FW: Cv study desig
|
|
Bookmark:
|
http://dida.library.ucsf.edu/tid/oxx11e10
|
|
| |
5.
Vigor
|
Document Date:
|
20000309
|
|
Author:
|
Scolnick, Edward
|
|
Recipient:
|
Shapiro, Deborah|Reicin, Alise|Nies, Alan
|
|
Document Type:
|
e-mail
|
|
Case Number:
|
Ernst v. Merck & Co. Inc., District Court of Brazoria County, Texas, Cause No. 19961*BHO2
|
|
Bates Number:
|
MRK-ABH0016219-4346
|
|
Exhibit Number:
|
186
|
|
Search Terms in Context:
|
To:
Shapiro, Deborah R.; Reicin, Alise S.; Nies, Alan S.
From:
Scolníck, Edward hÁ.
Ce
Scolnlck, Edward M.
Bec:
Date:
2000-03-09 23:18:40
Subject:
vigor
To all: I just received and went through the data. Thank you for sending it to me. There is no doubt about the pub data, very very strong, as expected, general safety is better than couid hope for in this patient population, incidences of hypertension, renal anything ,edema, liver, all great-very safe.very very safe. The CV events are clearly there. Since no obvious correlate right now ie not steroids , maybe smoking and prior a bit this is real. It is important to find out about the cases that oates told us about. When we present in May we should present those also if he will let us so it is clear to the world that this is class effect, all the ideas you talked about are important: pltpid antibodies-but 1 doubt it will correlate.Many vein tbosis in what is probably a somewhat restricted patient group. I think we should run an asa low dose endosc
|
|
Bookmark:
|
http://dida.library.ucsf.edu/tid/oxx05q10
|
|
| |
6.
Email re Vioxx label
|
Document Date:
|
20011016
|
|
Document Type:
|
e-mail
|
|
Case Number:
|
Ernst v. Merck & Co. Inc., District Court of Brazoria County, Texas, Cause No. 19961*BHO2
|
|
Bates Number:
|
MRK-ABW0004799
|
|
Exhibit Number:
|
346
|
|
Search Terms in Context:
|
: Scolnick, Edward M.
Sent: Monday, October IS, 2001 6:02 PM
To: Anstice, David VA
Subject: vioxx label
David Be assured v/e will not accept this label if we need to we will ask to go to an advisory committee meeting/Ed
Confidential - Subject To Protective Order
|
|
Bookmark:
|
http://dida.library.ucsf.edu/tid/oxx06e10
|
|
| |
7.
Email from Reicin dated 3/28/00 re Carlo Patrono Vigor
|
Document Date:
|
20030827
|
|
Author:
|
Reicin
|
|
Document Type:
|
e-mail
|
|
Case Number:
|
Brian Hermans v. Merck & Co,
|
|
Bates Number:
|
LEH0022978
|
|
Exhibit Number:
|
P248
|
|
Search Terms in Context:
|
To: Nies, Alan S.; Gertz, Barry J.
From: Reich, Ajise S.
Cc Ehrich, Elliot W.; Daniels, Brian F.; Scoinick, Edward M.; Slater, Eve- Blois, David W.
Bcc:
Date: 2000-03-2819:54:40
Subject FW: Carlo Patrono on VIGOR
I have attached a message from Martino re his discussions with Carlo Petrono. I think it would be worth walking
through the data with Cario. Do you think we should try and set up a teleconference?
Alise
From: Laurenzi, Martino
Sent: Tuesday, March 28, 2000 2:10 PM
To: Daniels, Brian F.; Ehrich, Elliot W.; Reicin, Alise S.
Cc: Chakhov, louri: de Jesus, Daniel G.; Guerra, Jorge G.; Hormbrey, Janet; Kyiish, Gregory S.; McKinney,
Errol S.; Moan, Andreas; Ruef, Tim; Salib, Atif; Schwartz, Juies; Yrivarren, Juan Luis
Subject: Carlo Patrono on VIGOR
Guys,
I met with Cario Patrono last Saturday in Rome. He had already been informed by other sources about the results of VIGOR, and
|
|
Bookmark:
|
http://dida.library.ucsf.edu/tid/oxx12n10
|
|
| |
8.
Email from Morrison to Quan
|
Document Date:
|
19970723
|
|
Document Type:
|
e-mail
|
|
Case Number:
|
Brian Hermans v. Merck & Co,
|
|
Bates Number:
|
MRK-AGO0002147
|
|
Exhibit Number:
|
D7158
|
|
Search Terms in Context:
|
Quan, Hui
From:
Morrison, Briggs
To:
Quan, Hui
Subject:
RE: Prot 023
Date:
Wednesday, July 23,1997 1:40PM
iohexol is in URINE_COLLECT_ASSAYS VIEW as glomerular filtration rate.
serum txb2, urinary NAG, urinary eicosanoids - we do not yet have in any form. Are promise by end of July and then we will put in the collector to feed database.
bwm
From: Quan, Hui
To: Morrison, Briggs
Subject: Prot 023
Date: Wednesday, July 23, 1997 12:24PM
Priority: High
Briggs,
according tq^the protocol, we need to analyze weight, blood pressures, urirf^ry sodium, urinaryjaotassium, creatinine clearance, iohexol clearance, serum txb2, urinaryNAG, urinary eicosanoids.
I saw weight and blood pressure data in VITAL VIEW; urinary sodium, urinary potassium and urinary creatinine in URINE_COLLECT_ASSAYS VIEW; serum sodium, serum potassium and serum creatinine in BLOOD_COLLECY_ASSAYS VIEW; and on data for other variables. Please confirm this is the current status.
If you have sample data subsets for other variables, I
|
|
Bookmark:
|
http://dida.library.ucsf.edu/tid/oxx17y10
|
|
| |
9.
Email re: VIGOR/RA label launch
|
Document Date:
|
20020412
|
|
Author:
|
Schechter, Adam
|
|
Recipient:
|
Kim, Peter|Scolnick, Edward|Lewent, Judy|McGlynn, Margie|Wainwright, Joan|Frazier, Kenneth|Anstice, David|Nichtberger, Steven
|
|
Document Type:
|
e-mail
|
|
Named Organization:
|
Merck & Co.
|
|
Case Number:
|
ATL-L-3553-05-MT|Cona et. al. v. Merck & Co., Inc
|
|
Bates Number:
|
MRKAAC0100438
|
|
Exhibit Number:
|
A690
|
|
Search Terms in Context:
|
is a summary of the day one accomplishments for the VIGOR/RA label launch. It is always impressive to me to see what people in a cross-functional team can do at Merck. The accomplishments below were very high quality and reflect a team effort across many divisions and departments including, MRL - Clinical and Regulatory, Public Affairs, Investor relations, Medical Affairs, Medical legal, Reprographics, Mail
|
|
Person Copied:
|
Gertz, Barry
|
|
Bookmark:
|
http://dida.library.ucsf.edu/tid/oxx02m10
|
|
| |
10.
Schechter Email
|
Document Date:
|
20020412
|
|
Document Type:
|
e-mail
|
|
Case Number:
|
Brian Hermans v. Merck & Co,
|
|
Bates Number:
|
MRK-AAC0100438
|
|
Exhibit Number:
|
D369
|
|
Search Terms in Context:
|
of the day one accomplishments for the VIGOR/RA label launch. It is always impressive to me to see what people in a cross-functional team can do at Merck. The accomplishments below were very high quality and reflect a team effort across many divisions and departments including, MRL - Clinical and Regulatory, Public Affairs, Investor relations, Medical Affairs, Medical legal, Reprographics, Mail room
|
|
Bookmark:
|
http://dida.library.ucsf.edu/tid/oxx16y10
|
|
| |
|
Prev
Next
|
